Figure 1. CT abdomen and pelvis demonstrating a possible hematoma in the bladder.
| Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc |
| Journal website http://www.journalmc.org |
Case Report
Volume 10, Number 6, June 2019, pages 179-182
Hemorrhagic Cystitis With Low-Dose Cyclophosphamide Therapy for Breast Cancer: A Rare Occurrence
Figure
Table
| Case 1 (current case) | Case 2 [7] | Case 3 [11] | Case 4 [11] | |
|---|---|---|---|---|
| Age in years | 63 | 62 | 67 | 65 |
| Treatment initiated | CP and docetaxel | CP and docetaxel | CP and adriamycin followed by CP and capecitabine | CP and capecitabine |
| Total dose received prior to symptoms | 600 mg/m2 | 600 mg/m2 | 60.8 g (600 mg/m2 for six cycles followed by 100 mg/day) | 78.4 g (100 mg/day × 14 days every 3 weeks) |
| Time from initiation of CP therapy to duration of symptoms | Within 24 h | 2 days | 30 months | 39 months |
| Treatment of HC | Continuous bladder irrigation and cystoscopic fulguration | Resolved spontaneously | Bladder irrigation with drainage, hyperbaric oxygen therapy and bilateral ureterostomy | Trans-urethral electric coagulation, continuous bladder irrigation, hyperbaric oxygen therapy |
| Subsequent CP use | Yes, three cycles with mesna infusion | Yes, three cycles with mesna infusion | No | No |
| Post treatment follow-up | No recurrence | No recurrence | No recurrence for 2 years | No recurrence for 6 months |